CLAIMS

1. A double-stranded microRNA mimic, comprising:

(a) a mature sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 11 to 14; and

(b) a passenger strand.

2. A double-stranded microRNA mimic according to Claim 1, in which the passenger strand comprises a sequence selected from the group consisting of SEQ ID NOs: 15 to 18.

3. A double-stranded microRNA mimic according to Claim 1 or 2, in which the passenger strand is inactivated by chemical modification.

4. Use of a double-stranded microRNA mimic according to Claim 1, 2 or 3 in the manufacture of a medicament for treating MPM.

5. Use according to Claim 4, in which the mimic is provided for administration with a minicell.

6. Use according to Claim 4 or 5, in which the mimic is provided for co-administration simultaneously or serially with an adjunct anticancer therapy.

7. Use of a microRNA mimic according to Claim 1, 2 or 3 in the manufacture of a medicament for increasing sensitivity of a MPM cancer cell to an anti-cancer therapy.

8. A microRNA mimic according to any of Claims 1, 2 or 3 for use in medicine.

CLAIMS

1. A double-stranded microRNA mimic, comprising:

(a) a mature sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 11 to 14; and

(b) a passenger strand.

2. A double-stranded microRNA mimic according to Claim 1, in which the passenger strand comprises a sequence selected from the group consisting of SEQ ID NOs: 15 to 18.

3. A double-stranded microRNA mimic according to Claim 1 or 2, in which the passenger strand is inactivated by chemical modification.

4. Use of a double-stranded microRNA mimic according to Claim 1, 2 or 3 in the manufacture of a medicament for treating malignant pleural mesothelioma (MPM).

5. Use according to Claim 4, in which the mimic is provided for administration with a minicell.

6. Use according to Claim 4 or 5, in which the mimic is provided for co-administration simultaneously or serially with an adjunct anticancer therapy.

7. Use of a microRNA mimic according to Claim 1, 2 or 3 and an adjunct anti-cancer therapy in the manufacture of a medicament for treating malignant pleural mesothelioma (MPM).

8. A microRNA mimic according to any of Claims 1, 2 or 3 for use in medicine.